Merck & Co., Inc.MRKNYSE
Loading
EBITDA Over TimeStrong
Percentile Rank93
3Y CAGR+6.0%
5Y CAGR+20.0%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
+6.0%/yr
vs +11.1%/yr prior
5Y CAGR
+20.0%/yr
Recent deceleration
Acceleration
-5.1pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $25.36B | -1.3% |
| 2024 | $25.71B | +272.2% |
| 2023 | $6.91B | -67.6% |
| 2022 | $21.32B | +19.1% |
| 2021 | $17.90B | +75.8% |
| 2020 | $10.18B | -10.5% |
| 2019 | $11.37B | -18.7% |
| 2018 | $13.99B | +17.1% |
| 2017 | $11.95B | +10.4% |
| 2016 | $10.82B | - |